Opus Genetics IRD Gain (Loss) on Derivative Instruments, Net, Pretax
Gain (Loss) on Derivative Instruments, Net, Pretax at other companies
Other financials
Where this comes from
Reported directly by Opus Genetics in its filing.
Tagged under the XBRL concept us-gaap:GainLossOnDerivativeInstrumentsNetPretax.
The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Opus Genetics's gain (loss) on derivative instruments, net, pretax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Opus Genetics's gain (loss) on derivative instruments, net, pretax?
- Opus Genetics (IRD) reported gain (loss) on derivative instruments, net, pretax of -$51.36M in Q1 2026.
- How has Opus Genetics's gain (loss) on derivative instruments, net, pretax changed year-over-year?
- Opus Genetics's gain (loss) on derivative instruments, net, pretax decreased by 1931.2% year-over-year, from $2.81M to -$51.36M.
- What is the long-term trend for Opus Genetics's gain (loss) on derivative instruments, net, pretax?
- Over 4 years (2021 to 2025), Opus Genetics's gain (loss) on derivative instruments, net, pretax has grown at a -23.6% compound annual growth rate (CAGR), from -$33.83M to -$11.52M.
- What does gain (loss) on derivative instruments, net, pretax mean?
- Represents the net change in the fair value of derivative financial instruments recognized in the income statement before tax effects. For a clinical-stage company, this often reflects volatility in warrant liabilities or embedded derivatives linked to financing arrangements. It highlights non-operating fluctuations that impact net income without affecting immediate cash flow.